Biotech · Public company · Woburn, MA, US
Replimune Group, Inc.
Ticker REPL · SEC CIK 0001737953
Track this companyFree. Adds Replimune Group, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials1513 recruiting or active
Pipeline programs29From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline29
- IpilimumabPhase 3 · Metastatic Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 3 · Metastatic Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 3 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Nivolumab + RelatlimabPhase 3 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- RP2Phase 3 · Metastatic Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Single-agent chemotherapyPhase 3 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Vusolimogene OderparepvecPhase 3 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- atezolizumabPhase 2 · Refractory Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- bevacizumabPhase 2 · Refractory Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- carboplatin and paclitaxelPhase 2 · Squamous Cell Carcinoma of Head and NeckClinicalTrials.gov · fetched Nov 12, 2026
- CCRT(concurrent chemoradiation therapy)Phase 2 · Squamous Cell Carcinoma of Head and NeckClinicalTrials.gov · fetched Nov 12, 2026
- CemiplimabPhase 2 · Cutaneous Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- DurvalumabPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- nivolumabPhase 2 · Squamous Cell Carcinoma of Head and NeckClinicalTrials.gov · fetched Nov 12, 2026
- nivolumabPhase 2 · Non-Small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- RP1Phase 2 · Cutaneous Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- RP1Phase 2 · Non-Small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- RP1, intra-tumoral injection, oncolytic virusPhase 2 · Merkel Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- RP2Phase 2 · Refractory Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- RP2Phase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- RP2 MonotherapyPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- RP3Phase 2 · Refractory Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- RP3Phase 2 · Squamous Cell Carcinoma of Head and NeckClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- RP3Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Observational study with no interventionsMelanomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials15
- Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal AdenocarcinomaPHASE2 · NOT_YET_RECRUITING · started Apr 1, 2027ClinicalTrials.gov NCT07059611 · fetched Nov 12, 2026
- Neoadjuvant RP2 + Nivolumab in Patients With MelanomaPHASE2 · NOT_YET_RECRUITING · started Dec 31, 2026ClinicalTrials.gov NCT07862530 · fetched Nov 12, 2026
- Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaPHASE2 · RECRUITING · started Jan 9, 2026ClinicalTrials.gov NCT06898970 · fetched Nov 12, 2026
- A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3RECRUITING · started Dec 12, 2025ClinicalTrials.gov NCT06887348 · fetched Nov 12, 2026
- Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous DiseasePHASE2 · RECRUITING · started Jan 1, 2025ClinicalTrials.gov NCT06623110 · fetched Nov 12, 2026
- A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaPHASE2_PHASE3 · RECRUITING · started Dec 17, 2024ClinicalTrials.gov NCT06581406 · fetched Nov 12, 2026
- Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCPHASE2 · RECRUITING · started Aug 1, 2024ClinicalTrials.gov NCT05733598 · fetched Nov 12, 2026
- VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]PHASE3 · RECRUITING · started Jul 11, 2024ClinicalTrials.gov NCT06264180 · fetched Nov 12, 2026
- RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node MetastasisEARLY_PHASE1 · RECRUITING · started Mar 7, 2024ClinicalTrials.gov NCT06216938 · fetched Nov 12, 2026
- Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHNPHASE2 · WITHDRAWN · started Jan 30, 2024ClinicalTrials.gov NCT05743270 · fetched Nov 12, 2026
- RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCPHASE2 · TERMINATED · started Jun 29, 2023ClinicalTrials.gov NCT05733611 · fetched Nov 12, 2026
- Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid TumoursPHASE1 · ACTIVE_NOT_RECRUITING · started Dec 29, 2020ClinicalTrials.gov NCT04735978 · fetched Nov 12, 2026
- Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin MalignanciesPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 15, 2020ClinicalTrials.gov NCT04349436 · fetched Nov 12, 2026
- Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Oct 8, 2019ClinicalTrials.gov NCT04050436 · fetched Nov 12, 2026
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 20, 2017ClinicalTrials.gov NCT03767348 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Oct 28, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 28, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Sep 16, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K/A · FORM 8-K/ASEC EDGAR · filed Aug 11, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 7, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 31, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Jun 29, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 29, 2026 · fetched Nov 12, 2026